Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes

OBJECTIVE: To evaluate the risk of serious adverse events among patients with type 2 diabetes mellitus initiating saxagliptin compared with oral antidiabetic drugs (OADs) in classes other than dipeptidyl peptidase-4 (DPP-4) inhibitors. RESEARCH DESIGN AND METHODS: Cohort studies using 2009–2014 data...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo Re, Vincent, Carbonari, Dena M, Saine, M Elle, Newcomb, Craig W, Roy, Jason A, Liu, Qing, Wu, Qufei, Cardillo, Serena, Haynes, Kevin, Kimmel, Stephen E, Reese, Peter P, Margolis, David J, Apter, Andrea J, Reddy, K Rajender, Hennessy, Sean, Bhullar, Harshvinder, Gallagher, Arlene M, Esposito, Daina B, Strom, Brian L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Epidemiology/Health Services Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574452/
https://www.ncbi.nlm.nih.gov/pubmed/28878934
http://dx.doi.org/10.1136/bmjdrc-2017-000400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574452/
https://www.ncbi.nlm.nih.gov/pubmed/28878934
http://dx.doi.org/10.1136/bmjdrc-2017-000400

Ejemplares similares